News

Model N Management to Present at the Raymond James 2023 TMT and Consumer Conference

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance today announced that Model N…

1 year ago

Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing

Halifax, Nova Scotia--(Newsfile Corp. - November 27, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…

1 year ago

Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib

The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or…

1 year ago

EchoNous and United Medical Instruments (UMI) Join Forces to Accelerate Kosmos Growth in the USA

REDMOND, WA / ACCESSWIRE / November 27, 2023 / EchoNous, a trailblazer in AI-enabled point-of-care ultrasound (POCUS) technology, is excited…

1 year ago

New Peer-Reviewed Study Shows That Olleyes VisuALL VRP is Comparable to HVF and Offers Valuable Supplement to Standard Automated Perimetry for Pediatric Patients

Study completed at Duke University shows that the VisuALL is suitable substitute for HVF when testing pediatric patients.SUMMIT, NJ /…

1 year ago

Blue Sky Specialty Pharmacy New Partnership With UCB’s Bimzelx(R) (Bimekizumab-Bkzx)

MOUNT PLEASANT, SC / ACCESSWIRE / November 27, 2023 / Blue Sky Specialty Pharmacy, a prominent provider of comprehensive specialty…

1 year ago

NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss…

1 year ago

Glioblastoma Foundation Hosts ‘Rock Against Glioblastoma’ (RAG), Shining a Spotlight on Deadliest Form of Brain Cancer

First Annual Music Festival Features Talented Lineup of Performers at the Legendary Cat's Cradle, Raising Vital Funds for Glioblastoma Research…

1 year ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerabilityCompany expects to engage FDA…

1 year ago

FSD Pharma Inc. Obtains Final Order for Plan of Arrangement

TORONTO, ON / ACCESSWIRE / November 27, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

1 year ago